Bukwang Pharm signs Dexid licensing and supply deal with Saudi Arabia’s NASAQ
Bitget2026/11/04 01:20- Bukwang Pharm signed a technology licensing and exclusive supply agreement with Saudi Arabia’s NASAQ for diabetic polyneuropathy treatment Dexid on November 4, 2026.
- The initial five-year agreement renews automatically for two-year periods.
- Five-year minimum purchases total about USD 2.66 million (KRW 3.7 billion), versus projected sales of USD 4.53 million (KRW 6.3 billion).
- NASAQ will handle Saudi regulatory approval, marketing and distribution; Bukwang will support approval and supply finished products.
- The agreement includes technology transfer for local production, supporting Saudi Arabia’s Vision 2030 pharmaceutical localization policy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
